Etude : VALYM /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme / Nom
Situation thérapeutique
Traitement
Cadre réglementaire
MÀJ
Présentation de l'étude
Acronyme / Nom : VALYM

Situation thérapeutique : Induction

Traitement : Thérapie ciblée

Cadre réglementaire : RIPH1

Dernière MÀJ : 29/11/2021
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Étude de phase II en ouvert évaluant le valemetostat tosylate en monotherapie chez des patients atteints d’un lymphome à cellules B en rechute ou réfractaire

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C82 - Lymphome folliculaire

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C83 - Lymphome non folliculaire

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C85 - Lymphome non hodgkinien, de types autres et non précisés

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C81 - Lymphome de Hodgkin

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C88 - Maladies immunoprolifératives malignes
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts.
Up to 141 patients will be enrolled in 6 different cohorts:
- Cohort 1: Aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rerrangement, transformed indolent lymphoma and grade 3b follicular lymphoma) (with at least 8 EZH2 mutant)
- Cohort 2: Follicular Lymphoma (grade 1, 2, 3a) EZH2 wild-type
- Cohort 2bis: Follicular Lymphoma (grade 1, 2, 3a) EZH2 mutant (gain of function mutations)
- Cohort 3: Mantle Cell Lymphoma (MCL)
- Cohort 4: Marginal Zone Lymphoma (MZL) and others indolent lymphoma (Waldenström macroglobulinemia)
- Cohort 5: Hodgkin Lymphoma (HL)

SINGLE ARM ASSIGNMENT:
Experimental arm: Each cycle consists of 28 days. Valemetostat tosylate (DS-3201b) is given continuously at 200 mg once daily (QD).
The total duration is expected to be approximately 3 years, assuming an expected enrollment duration of 2 years and a minimum duration of valemetostat tosylate (DS- 3201b) administration of 12 cycles of 28 days for the last enrolled patient.

MAIN OBJECTIVE:
Evaluate efficacy of valemetostat tosylate (DS-3201b) monotherapy in relapsed/refractory B cell lymphoma patients within 6 distinct cohorts.

SECONDARY OBJECTIVES:
- Rate of complete response (CR)
- Progression-free survival (PFS)
- Duration of response (DOR)
- Time to response (TTR)
- Safety
- To evaluate the plasma pharmacokinetics of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a).

Phase : II

Stade : NA

Rechute, Réfractaire
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : 1. Participants with confirmed histological diagnosis of B-cell non-Hodgkin's lymphoma of aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rerrangement, transformed indolent lymphoma and grade 3b follicular lymphoma), FL (grade 1, 2, 3a), MCL, MZL or other indolent lymphoma (Waldenström macroglobulinemia), or HL according to the World Health Organization (WHO) 2016 classification of hematopoietic and lymphoid tissue
2. Participant who had progressive disease (PD) or did not have a response (CR or PR) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
3. Participant who has measurable disease by the Lugano criteria (ie longest diameter of a nodal site > 1.5cm and/or longest diameter of an extranodal site > 1.0 cm)
4. Participant who had previous standard therapy with at least:
(note: patients having received prior CAR-T therapy can be enrolled):
4a. For aggressive B-cell lymphoma: 1 prior line of therapy (in transformed indolent lymphoma patient must have received at least one line of treatment containing an anthracycline-based regimen before or after transformation) containing an anti-CD20 antibody and an anthracycline (unless anthracycline-based therapy is contraindicated) and if patient is considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:
- Relapsed following, or refractory to, previous ASCT
- Ineligible for intensification treatment due to age or significant comorbidity
- Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
- Refused intensification treatment and/or ASCT
4b. For FL, MZL and other indolent NHL: 2 prior lines of systemic therapy with at least one anti-CD20 monoclonal antibody. Local involved field radiotherapy for limited stage disease is not considered as a previous line. Subjects with prior ASCT may be included. Note: for Splenic Marginal Zone Lymphoma (SMZL), splenectomy is considered as one line; for Extranodal Marginal Zone Lymphoma (ENMZL), Helicobacter pylori eradication is not considered as a previous line.
4c. For MCL: 2 prior lines including at least one immunochemotherapy and one BTK inhibitor.
4d. For HL: 3 prior lines including at least one line with anthracycline-based chemotherapy (unless anthracycline-based therapy is contraindicated), one line containing brentuximab-vedotin and one line containing an anti-PD1 or anti-PDL1 antibody and must be considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:
- Relapsed following, or refractory to, previous ASCT
- Did not achieve at least a partial response to a standard salvage regimen
- Ineligible for intensification treatment due to age or significant comorbidity
- Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
- Refused intensification treatment and/or ASCT
5. Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
6. Adequate renal function defined as calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula
7. Adequate bone marrow function
8. Adequate liver function:
9. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation
10. Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis)
11. Subjects with a history of hepatitis B or C are eligible on the condition that subjects have adequate liver function and are hepatitis B surface antigen negative and have undetectable serum HBV DNA and HCV RNA, respectively.
12. Females of childbearing potential must agree to use an highly effective birth control methods (defined in §13.6.1) during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 3 months after discontinuation of study treatment
13. Males with partners of childbearing potential must agree to use highly effective birth control methods during the study and 3 months after last treatment administration
14. Male and female participant ≥18 years of age at the time of informed consent
15. Patient covered by any social security system (France)
16. Patient who understands and speaks one of the country official language
17. Participant who has provided written consent to participate in the study

Critères de non-inclusion : 1. Participant with prior exposure to EZH2 inhibitor
2. Participant with active lymphomatous involvement of the central nervous system (CNS) at screening
3. Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy), clinically significant toxicities have not resolved to ≤ Grade 1 per CTCAE version 5.0, or prior treatment-related toxicities are clinically unstable and clinically significant at time of enrollment.
4. Major surgery within 4 weeks before the first dose of study drug.
5. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of the drug
6. Subjects currently taking medications that are known moderate or strong CYP3A inducers (refer to Appendix 7 for a list of example drugs)
o If currently used, these medications need to be discontinued at least 14 days prior to study drug administration; replacement by alternative medications that are not moderate or strong CYP3A inducers can be considered according to medical need
7. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine)
8. Use of any standard or experimental anti-cancer drug therapy within 4 weeks or a minimum of 3 half lives of the drug, whatever the shortest prior to first administration of study drug,
9. History of CAR T-cells therapy within 30 days prior to the first dose of study drug
10. History of autologous or allogeneic HCT within 90 days prior to the first dose of study drug
11. Patients taking corticosteroids within 2 weeks prior to first administration of study drug, unless administered at a cumulated dose equivalent of prednisone to ≤ 10mg/ day (within these 2 weeks).
12. Participant with significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia
13. Subjects with malignancies other than B cell lymphomas except subjects who have been disease-free for 2 years (subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).
14. Positive serology of human immunodeficiency virus (HIV)
15. Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 470 milliseconds (msec) (obtained on average of 3 ECGs)
16. Participant with venous thrombosis or pulmonary embolism not treated
17. Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis
18. Participant with active infection requiring systemic therapy
19. Woman who are pregnant (positive serum pregnancy test at screening) or breastfeeding
20. Participant who were deemed as inappropriate to participate in the study by the investigator or sub-investigator
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT04842877
Promoteur :
lysarc
Type de sponsor : Institutionnel
Centre hospitalier Lyon sud, secteur sainte Eugénie, pavillon 6E
69001 LYON 01

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Hospitalier Universitaire de Lille - 2 Avenue Oscar Lambret - 59000 LILLE

Investigateur :
Professeur Franck MORSCHHAUSER

TEC / ARC / IDE :
Secrétariat de recherche
fanny.miquel@
chru-lille.fr
03.20.44.57.13

Statut de l'essai : OUVERT

MAJ : 15/11/2021